PMVP

Pmv Pharmaceuticals Inc

PMVP, USA

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

https://www.pmvpharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PMVP
stock
PMVP

PMV Pharmaceuticals (NASDAQ:PMVP) Trading Down 1.7% – Here’s Why Defense World

Read more →
PMVP
stock
PMVP

PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.6

Analyst Picks

Strong Buy

4

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.54

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-17.40 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-15.73 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.11

Low 1

High 0.3

Investors

* Institutions hold a combined 73.13% of the total shares of Pmv Pharmaceuticals Inc

1.

Orbimed Advisors, LLC

(12.2196%)

since

2025/06/30

2.

BML Capital Management LLC

(9.4356%)

since

2025/06/30

3.

Sio Capital Management, LLC

(7.0491%)

since

2025/06/30

5.

Euclidean Capital LLC

(4.9587%)

since

2025/06/30

6.

Alkeon Capital Management, LLC

(4.4203%)

since

2025/06/30

7.

Vanguard Group Inc

(4.0641%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.8154%)

since

2025/07/31

9.

Meridian Small Cap Growth Legacy

(2.3692%)

since

2025/06/30

10.

ArrowMark Small Cap Gro

(2.3692%)

since

2025/06/30

11.

ACAP Strategic A

(2.1647%)

since

2025/06/30

12.

BlackRock Inc

(2.1524%)

since

2025/06/30

13.

Stonepine Capital Management Llc

(1.5964%)

since

2025/06/30

14.

D. E. Shaw & Co LP

(1.2222%)

since

2025/06/30

15.

SQUAD Aguja Opportunities I

(1.0757%)

since

2025/05/31

16.

Aldebaran Capital LLC

(0.9721%)

since

2025/06/30

17.

Two Sigma Advisers, LLC

(0.9166%)

since

2025/06/30

18.

Peapod Lane Capital LLC

(0.8543%)

since

2025/06/30

19.

Geode Capital Management, LLC

(0.8166%)

since

2025/06/30

20.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7005%)

since

2025/07/31

21.

Two Sigma Investments LLC

(0.55%)

since

2025/06/30

22.

BlackRock Advantage Small Cap Core Instl

(0.5292%)

since

2025/07/31

23.

Assenagon Asset Management SA

(0.4964%)

since

2025/06/30

24.

Citadel Advisors Llc

(0.4839%)

since

2025/06/30

25.

RBF LLC

(0.4634%)

since

2025/06/30

26.

Fidelity Extended Market Index

(0.3948%)

since

2025/07/31

27.

State Street Corp

(0.2974%)

since

2025/06/30

28.

Bridgeway Capital Management, LLC

(0.2808%)

since

2025/06/30

29.

iShares Micro-Cap ETF

(0.1806%)

since

2025/08/31

30.

Extended Equity Market Fund K

(0.1597%)

since

2025/06/30

31.

Fidelity Total Market Index

(0.1355%)

since

2025/07/31

32.

Bridgeway Ultra-Small Company

(0.1319%)

since

2025/06/30

33.

Invesco Technology S&P US Sel Sec ETF

(0.1313%)

since

2025/07/31

34.

Fidelity Series Total Market Index

(0.1148%)

since

2025/07/31

35.

Goldman Sachs Absolute Ret Trckr Instl

(0.1112%)

since

2025/06/30

36.

Bridgeway Ultra-Small Company Market

(0.1102%)

since

2025/06/30

37.

Spartan Extended Market Index Pool F

(0.0952%)

since

2025/07/31

38.

Northern Trust Extended Eq Market Idx

(0.095%)

since

2025/06/30

39.

NT Ext Equity Mkt Idx Fd - L

(0.095%)

since

2025/06/30

40.

NT Ext Equity Mkt Idx Fd - NL

(0.0862%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.4

EPS Estimate

-0.4067

EPS Difference

0.0067

Surprise Percent

1.6474%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(6)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Strong Net-Net(6.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.